JP2016503391A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503391A5
JP2016503391A5 JP2015538050A JP2015538050A JP2016503391A5 JP 2016503391 A5 JP2016503391 A5 JP 2016503391A5 JP 2015538050 A JP2015538050 A JP 2015538050A JP 2015538050 A JP2015538050 A JP 2015538050A JP 2016503391 A5 JP2016503391 A5 JP 2016503391A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
fluoro
item
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015538050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503391A (ja
JP6385939B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/065633 external-priority patent/WO2014063024A1/en
Publication of JP2016503391A publication Critical patent/JP2016503391A/ja
Publication of JP2016503391A5 publication Critical patent/JP2016503391A5/ja
Application granted granted Critical
Publication of JP6385939B2 publication Critical patent/JP6385939B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015538050A 2012-10-19 2013-10-18 Mek阻害剤の調製およびmek阻害剤を含む製剤 Active JP6385939B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716169P 2012-10-19 2012-10-19
US61/716,169 2012-10-19
PCT/US2013/065633 WO2014063024A1 (en) 2012-10-19 2013-10-18 Preparation of and formulation comprising a mek inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018109486A Division JP6737838B2 (ja) 2012-10-19 2018-06-07 Mek阻害剤の調製およびmek阻害剤を含む製剤

Publications (3)

Publication Number Publication Date
JP2016503391A JP2016503391A (ja) 2016-02-04
JP2016503391A5 true JP2016503391A5 (enExample) 2016-12-01
JP6385939B2 JP6385939B2 (ja) 2018-09-05

Family

ID=50488781

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015538050A Active JP6385939B2 (ja) 2012-10-19 2013-10-18 Mek阻害剤の調製およびmek阻害剤を含む製剤
JP2018109486A Active JP6737838B2 (ja) 2012-10-19 2018-06-07 Mek阻害剤の調製およびmek阻害剤を含む製剤
JP2019149828A Pending JP2019194272A (ja) 2012-10-19 2019-08-19 Mek阻害剤の調製およびmek阻害剤を含む製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018109486A Active JP6737838B2 (ja) 2012-10-19 2018-06-07 Mek阻害剤の調製およびmek阻害剤を含む製剤
JP2019149828A Pending JP2019194272A (ja) 2012-10-19 2019-08-19 Mek阻害剤の調製およびmek阻害剤を含む製剤

Country Status (23)

Country Link
US (7) US9238627B2 (enExample)
EP (3) EP3702351B1 (enExample)
JP (3) JP6385939B2 (enExample)
CN (3) CN109456272A (enExample)
AR (1) AR099630A1 (enExample)
BR (1) BR112015008623B1 (enExample)
CA (2) CA3079071C (enExample)
CY (1) CY1122670T1 (enExample)
DK (2) DK2909182T3 (enExample)
ES (2) ES2971077T3 (enExample)
FI (1) FI3702351T3 (enExample)
HR (1) HRP20240033T1 (enExample)
HU (2) HUE065433T2 (enExample)
JO (1) JOP20130304B1 (enExample)
LT (1) LT3702351T (enExample)
PL (2) PL3702351T3 (enExample)
PT (2) PT2909182T (enExample)
RS (1) RS65117B1 (enExample)
RU (2) RU2669391C2 (enExample)
SI (2) SI2909182T1 (enExample)
SM (1) SMT202400044T1 (enExample)
TW (1) TWI650316B (enExample)
WO (1) WO2014063024A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2909182T1 (sl) 2012-10-19 2020-03-31 Array Biopharma Inc. Priprava inhibitorja MEK in formulacije, ki obsegajo inhibitor MEK
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
UA125436C2 (uk) 2016-06-03 2022-03-09 Еррей Біофарма, Інк. Фармацевтичні комбінації
CN111646946A (zh) * 2017-11-14 2020-09-11 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US11395823B2 (en) * 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
WO2020212832A1 (en) * 2019-04-16 2020-10-22 Alembic Pharmaceuticals Limited Process of preparation of benzimidazole compounds
WO2021116901A1 (en) * 2019-12-09 2021-06-17 Biocon Limited Forms of binimetinib and process for preparation thereof
AU2021358394A1 (en) 2020-10-05 2023-04-13 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma
CN112679438A (zh) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 制备司美替尼的方法
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス, インコーポレイテッド 併用療法
WO2023084489A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
WO2023131976A1 (en) * 2022-01-06 2023-07-13 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-n-(2hydroxyethoxy)-1-methyl-1h-benzimidazole-6-carboxamide
WO2024003942A1 (en) * 2022-07-01 2024-01-04 Natco Pharma Limited An improved process for the preparation of selumetinib sulfate
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
FR3159741A1 (fr) 2024-03-04 2025-09-05 Pierre Fabre Medicament Formulation topique comprenant du binimetinib
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0105113A3 (en) * 1999-01-13 2004-11-29 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds
AU6068600A (en) * 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
PL401638A1 (pl) * 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2005009975A2 (en) * 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
EP1904061B1 (en) 2005-06-23 2018-12-26 Array Biopharma, Inc. SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS
US8039637B2 (en) 2005-06-23 2011-10-18 Array Biopharma Inc. Process for preparing benzimidazole compounds
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US20090030058A1 (en) * 2005-12-21 2009-01-29 Mohammed Pervez Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
AU2008282338B2 (en) * 2007-07-30 2015-02-12 Ardea Biosciences, Inc. Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
US8022057B2 (en) * 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
JP2012524114A (ja) * 2009-04-21 2012-10-11 ノバルティス アーゲー Mek阻害剤としてのヘテロ環式化合物
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
MX2014002480A (es) 2011-09-01 2014-03-27 Novartis Ag Uso del compuesto organico para el tratamiento del sindrome de noonan.
SI2909182T1 (sl) 2012-10-19 2020-03-31 Array Biopharma Inc. Priprava inhibitorja MEK in formulacije, ki obsegajo inhibitor MEK

Similar Documents

Publication Publication Date Title
JP2016503391A5 (enExample)
RU2015118572A (ru) Получение и составление композиции, содержащей ингибитор мек
JP6309057B2 (ja) ヒドラジド含有核輸送調節因子およびその使用
TWI749934B (zh) 製備2-氟-4-甲基-5-(4-環丙基-1h-咪唑-1-基)苯甲酸之方法
RU2581585C2 (ru) Способ получения 4-{4-[({[4-хлор-3-(трифторметил) фенил] амино}-карбонил) амино]-3-фторфенокси}-n-метилпиридин-2-карбоксамида, его солей и моногидрата
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
JP6267213B2 (ja) 5−(2,6−ジ−4−モルホリニル−4−ピリミジニル)−4−トリフルオロメチルピリジン−2−アミンを製造するための改良された方法
CN104936961B (zh) (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法
EP3672968B1 (en) Solid state form of ribociclib succinate
JP2010503694A5 (enExample)
EP2707367B1 (en) Methods for preparing naphthyridines
CN101967140A (zh) 氘代克里唑蒂尼及其衍生物、制备方法和应用
TW201920196A (zh) 作為vanin抑制劑之雜芳族化合物
AU2007267612A1 (en) Preparation and utility of substituted carboxylic acid compounds
WO2016074532A1 (zh) 艾立替尼的制备方法
CA2565629A1 (en) Process for preparing atazanavir bisulfate and novel forms
TW201831495A (zh) 製備細胞毒性苯二氮平衍生物之方法
KR20190065414A (ko) 에라바사이클린의 결정질 형태
CA2890961A1 (en) Novel polymorphs of azilsartan medoxomil
CN102675395B (zh) 醋酸乌利司他的多晶型及其制备方法
KR20160068799A (ko) 신규 화합물
TW201041855A (en) New process for preparing
JP2020073523A (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
CN106608869A (zh) 一类组蛋白去甲基化酶jmjd3抑制剂及其制备方法和用途
CN105985329B (zh) 一种新的泊沙康唑化合物制备方法